Padeliporfin

Summary

Padeliporfin (CHEMBL4594284) is an approved small molecule (ATC L01XD07); indicated across 6 conditions including neoplasm and non-small cell lung carcinoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L01XD07
• Indications: 6 conditions
• Clinical trials: 4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594284
Name	Padeliporfin
Type	Small molecule
Max phase	4
ATC	L01XD07

Also known as: Padeliporfin, Padeliporfina, Padeliporfine, WST-11, Wst11, WST11, PADELIPORFIN

Parent form; salt/anhydrous children: CHEMBL4594285

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616

4 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
cholangiocarcinoma	2	MONDO:0019087	EFO:0005221
urothelial carcinoma	1	MONDO:0040679	EFO:0008528
kidney cancer	1	MONDO:0002367	MONDO:0002367

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE2	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00707356	PHASE2	COMPLETED	Study of WST11 in Patients With Localized Prostate Cancer
NCT00974662	PHASE2	TERMINATED	Study Using WST11 in Patients With Obstructing Endobronchial Non-Small Cell Lung Cancer
NCT00975039	PHASE2	TERMINATED	Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma
NCT00975429	PHASE2	COMPLETED	Study Using WST11 in Patients With Localized Prostate Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).